StockNow
Calendar
Log in
U.S. Markets

Eli Lilly's (LLY) Omvoh meets the primary endpoint of clinical remission in a Phase 3 paediatric ulcerative colitis trial, becoming the first IL-23p19 inhibitor to report one-year Phase 3 results in this patient population

StockNow breaking-news AI analysis

The supplied headline reports Omvoh met a pediatric ulcerative colitis Phase 3 primary endpoint and describes a first one-year reporting milestone; it provides no detailed results.

1 stocks
LLYEli Lilly & Co.$1,250.80Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US President Trump is reportedly mulling an attack on oil and military facilities in Iran's Kharg Island, ILNA reports citing UAE press

Geopolitics

"A breakthrough is expected to be announced this week to halt the escalation between Washington and Tehran", Al Araby Al Jadeed reports citing a source

FX/Bonds

[MARKET UPDATE] Bout of USD strength weighs on G10 peers, with EUR/USD falling beneath 1.1200, to a recent low of 1.1187; no clear driver